Escitalopram updated on 07-01-2025

Persistent pulmonary hypertension

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13122
R50029		 Marks (Controls exposed to Bupropion), 2021 Pulmonary Hypertension during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 3.50 [0.17;73.20] C 2/581   0/406 2 581
ref
S6079
R15819		 Kieler, 2012 Persistent pulmonary hypertension of the newborn 2nd and/or 3rd trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 1.30 [0.20;9.50] 1/557   1,935/1,588,140 1,936 557
ref
Total 2 studies 1.73 [0.34;8.82] 1,938 1,138
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Marks (Controls exposed to Bupropion), 2021Marks, 2021 1 3.50[0.17; 73.20]258129%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Kieler, 2012Kieler, 2012 1.30[0.20; 9.50]1,93655771%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.73[0.34; 8.82]1,9381,1380.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls exposed to Bupropion;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.73[0.34; 8.82]1,9381,1380%NAMarks (Controls exposed to Bupropion), 2021 Kieler, 2012 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.30[0.19; 8.96]1,936557 -NAKieler, 2012 1 exposed to other treatment, sickexposed to other treatment, sick 3.50[0.17; 73.20]2581 -NAMarks (Controls exposed to Bupropion), 2021 1 Tags Adjustment   - No  - No 3.50[0.17; 73.20]2581 -NAMarks (Controls exposed to Bupropion), 2021 1   - Yes  - Yes 1.30[0.19; 8.96]1,936557 -NAKieler, 2012 1 Monotherapy   - no or not specified  - no or not specified 1.30[0.19; 8.96]1,936557 -NAKieler, 2012 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 3.50[0.17; 73.20]2581 -NAMarks (Controls exposed to Bupropion), 2021 1 All studiesAll studies 1.73[0.34; 8.82]1,9381,1380%NAMarks (Controls exposed to Bupropion), 2021 Kieler, 2012 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.30[0.19; 8.96]1,936557 -NAKieler, 2012 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.50[0.17; 73.20]2581 -NAMarks (Controls exposed to Bupropion), 2021 10.510.01.0